Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (12): 767-768.
DOI: 10.19803/j.1672-8629.2019.12.14
ZHANG Yan, WANGJiajia*, WANGXiaolei
Received:2019-12-18
Revised:2019-12-18
Online:2019-12-15
Published:2019-12-18
CLC Number:
ZHANG Yan, WANGJiajia, WANGXiaolei. One Case of Dyspnea and Skin Rash Induced by Parecoxib Sodium for Injection[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 767-768.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2019.12.14
| [1] 卫生部. 药品不良反应报告和监测管理办法[S].卫生部令第 81号,2011. [2] 冯雪, 刘建平, 陈薇. 不良反应系统综述/meta分析方法[J]. 中国药物警戒, 2017, 14(5): 298-303. [3] 赵世丹, 鲁仲平. 影响个例药品不良反应报告评价的因素[J]. 中国药物警戒, 2012, 9(9): 553-554. [4] 崔向丽, 赵志刚, 陈丽, 等. 新型注射用选择性 COX-2抑制剂帕瑞昔布钠[J]. 中国新药杂志, 2009, 18(14):1283-1286. [5] Cheer S M, Goa K L.Parecoxib (parecoxib sodium)[J]. Drugs,2001, 61(8): 1133-1141. [6] Noveck R J, Kuss M E, Qian J, et al.Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirin-mediated platelet function[J]. Regional anesthesia and pain medicine, 2001, 26(2; SUPP): 19. [7] Du X, Gu J.The efficacy and safety of parecoxib for reducing pain and opioid consumption following total knee arthroplasty: a meta-analysis of randomized controlled trials[J]. International Journal of Surgery, 2018, (59): 69-74. [8] KarimA,LaurentA,Slater M E, et al. A pharmacokinetic study of intramuscular (im) parecoxib sodium in normal subjects[J]. The Journal of Clinical Pharmacology, 2001,41(10): 1111-1119. [9] Dalpiaz A S, Peterson D.Parecoxib: a shift in pain management?[J]. Expert review of neurotherapeutics,2004, 4(2): 165-177. [10] Essex M N, Cheung R, Li C, et al.Safety of parecoxib when used for more than 3 days for the management of posto-perative pain[J]. Pain management, 2017, 7(5): 383-389. |
| [1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
| [2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
| [3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
| [4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
| [6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
| [7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
| [8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
| [9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
| [10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
| [11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
| [12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
| [13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
| [14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
| [15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
